Skip to main content

Month: March 2023

Nextech3D.ai Announces Its AI-Powered SaaS Platform Toggle3D Experiences a +963% Jump in Users in 60-Days Crossing Over 1000 Users

Toggle3D Gaining Traction in $160 Billion Global CAD-3D, Sees Adoption Accelerating in 2023 TORONTO, March 23, 2023 (GLOBE NEWSWIRE) — via InvestorWire — Nextech3D.AI (formally “Nextech AR Solutions Corp” or the “Company”) (OTCQX: NEXCF) (CSE: NTAR) (FSE: EP2), a Generative AI-Powered 3D model supplier for Amazon, P&G, Kohls and other major e-commerce retailers is pleased to announce its AI-powered SaaS CAD to 3D Design Platform, Toggle3D.ai has crossed over 1000 sign-ups on the platform. Toggle3D.ai enables the conversion, texturing, customizing and sharing of the highest quality 3D models at scale, using CAD files. Since the Beta launch, the platform has attracted a variety of users such as designers, developers, 3D artists, entrepreneurs and creators, reaching over 1000 users on the platform...

Continue reading

Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results

– Company ended the year with $50.6 million in cash, expected to fund operations through 2024 and into 2025– Executing strategy to streamline advancement of development programs, build upon growing body of data across pipeline, and progress towards go/no-go decision milestones– Ongoing efforts to accelerate recruitment for our DETECT trial and establish partnering rights to Macrilen™ in the U.S. and Canada TORONTO, ONTARIO, March 23, 2023 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the year ended December 31, 2022. “Over the course of 2022 we made important pipeline progress and timely...

Continue reading

Palisade Bio Reports Year End 2022 Financial Results and Provides Corporate Update

Phase 2 topline data readout for prevention of post-surgical abdominal adhesions on track for Q2 2023 Strong balance sheet with sufficient cash expected to fund operations into mid-2024 Carlsbad, CA, March 23, 2023 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today reported its financial results for the full year 2022 and provided a corporate update. “Our team has made great progress executing our operational plan to strengthen our financial profile, focus our pipeline and position the Company for important near-term data readouts. With the cash proceeds from our recently completed financings and exercises of warrants, we believe we are in a strong financial position to build on this...

Continue reading

Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update

– Completed enrollment of CT1812 Phase 2 SEQUEL study for mild-to-moderate Alzheimer’s disease – Received FDA clearance for Phase 2 START Study of CT1812 in early Alzheimer’s disease – Received FDA clearance for IND for Phase 2 study of CT1812 in 240 patients with geographic atrophy secondary to dry AMD – Secured equity commitment of up to an additional $35M enabling potential access to capital – Connecting with neuroscience community through ongoing Cognition Conversations podcast series – Call scheduled today at 8:00 a.m. ET to discuss results PURCHASE, N.Y., March 23, 2023 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the “Company”...

Continue reading

Knight Therapeutics Reports Fourth Quarter and Year-End 2022 Results

Achieves Record Annual Revenues and EBITDA MONTREAL, March 23, 2023 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a leading Pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2022. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. Financial information as at and for the year ended December 31, 2022 is unaudited. 2022 Highlights FinancialsRevenues were $293,563, an increase of $50,085 or 21% over prior year. Gross margin of $138,061 or 47% of revenues compared to $115,412 or 47% of revenues in prior year. Adjusted EBITDA1 was $54,032, an increase of $16,027 or 42% over prior year. Net loss on financial assets...

Continue reading

Nokia chosen by CANARIE as sole IP router provider of ultra-high-capacity backbone network for Canadian research, education and innovation

Press Release Nokia chosen by CANARIE as sole IP router provider of ultra-high-capacity backbone network for Canadian research, education and innovationNokia 7750 Service Router delivers unmatched performance and reliability to support vital research in climate science, clean energy, medicine, cybersecurity and more High throughput capacity and availability, transferring petabyte-sized files for researchers around the world23 March 2023Espoo, Finland – Nokia today announced that CANARIE, the high-speed backbone of Canada’s National Research and Education Network (NREN), has chosen the Nokia 7750 Service Router as the IP/MPLS platform to support its more than 34,000 km network connecting 13 provincial and territorial networks to each other and to more than 100 NRENs around the world. CANARIE and its partner networks enable breakthrough...

Continue reading

Major Drilling Announces Normal Course Issuer Bid

MONCTON, New Brunswick, March 23, 2023 (GLOBE NEWSWIRE) — Major Drilling Group International Inc. (TSX: MDI) (“Major Drilling” or the “Company”), one of the world’s largest drilling services companies primarily serving the mining industry, announced today that the Toronto Stock Exchange (“TSX”) has accepted its notice of intention to make a normal course issuer bid (the “NCIB Program”) to purchase outstanding common shares of Major Drilling (the “Common Shares”) on the open market in accordance with the rules of the TSX. Pursuant to the NCIB Program, Major Drilling may purchase, from time to time, in aggregate up to 4,150,251 Common Shares (being approximately 5% of the 83,005,029 issued and outstanding Common Shares of Major Drilling as of March 15, 2023) over a 12-month period commencing on...

Continue reading

Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients

Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapyThis potentially enables treatment for patients with cold tumors, normally unresponsive to immunotherapyCOPENHAGEN, Denmark, March 23, 2023 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the discovery and development of AI-powered immunotherapies today announces that it has developed a new proprietary AI platform technology ObsERV™ to identify a new source of targets for personalized cancer therapy, potentially enabling treatment of patients that are currently considered unresponsive to cancer immunotherapy. ObsERV™, Evaxion’s new proprietary AI platform technology, identifies patient-specific virus targets, so-called ERVs...

Continue reading

Auctions of mortgage covered bonds for the refinancing of FlexKort®, RD Cibor6® and RD Euribor3®

To Nasdaq Copenhagen A/S   Executive Board Lersø Parkalle 100 DK-2100 København Ø www.rd.dk Telephone +45 7012 5300 23 March 2023  Company Announcement number 22/2023 Auctions of mortgage covered bonds for the refinancing of FlexKort®, RD Cibor6® and RD Euribor3® Realkredit Danmark will hold auctions on SDRO’s for the refinancing of FlexKort®, RD Cibor6® and RD Euribor3® as of 1 July 2023. The auctions will be held on 24 – 25 May 2023. Realkredit Danmark will open two new mortgage covered bonds (SDRO’s) to put on the auctions for the refinancing of RD Cibor6® and RD Euribor3®, respectively. The underlying bond to RD Cibor6® will be used for new loan offers at a later stage whereas the underlying bond to RD Euribor3® will be used for new loan offers immediately after the refinancing has taken place. At the auctions,...

Continue reading

Nano Dimension’s Chairman and CEO Answers Questions on the Company’s Products, Materials and variety of Technologies

Insights Into the Important Advancements Driving Industry 4.0 Digital Manufacturing Solutions Waltham, Mass., March 23, 2023 (GLOBE NEWSWIRE) —  Nano Dimension Ltd. (Nasdaq: NNDM, “Nano Dimension” or the “Company”), a leading supplier of Additively Manufactured Electronics (“AME”) and multi-dimensional polymer, metal & ceramic Additive Manufacturing (“AM”) 3D printers, released a video in which Yoav Stern, Chairman and Chief Executive Officer, responds to questions from shareholders about the Company’s products and technologies. Yoav Stern sheds light on the newest advancements that are underpinning the Company’s progress in providing new digital manufacturing solutions that are realizing Industry 4.0 capabilities for mechanical and electronic Additive Manufacturing products, materials and applications. Click here to watch...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.